- ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Market Perform rating at Leerink Partners.
- AC Immune SA (NASDAQ:ACIU) initiated with Outperform rating at Leerink.
- Adamas Pharmaceuticals (NASDAQ:ADMS) resumed with Outperform rating and $20 (75% upside) price target at Leerink.
- Aerie Pharmaceuticals (NASDAQ:AERI) initiated with Outperform rating and $64 (43% upside) price target at Oppenheimer.
- Allergan (NYSE:AGN) resumed with Outperform rating and $220 (34% upside) price target at Leerink. Shares down a fraction premarket.
- Alkermes plc (NASDAQ:ALKS) resumed with Market Perform rating at Leerink.
- GW Pharmaceuticals (NASDAQ:GWPH) initiated with Outperform rating and $185 (38% upside) price target at Leerink.
- Neurocrine Biosciences (NASDAQ:NBIX) initiated with Market Perform rating at Leerink.
- Molina Healthcare (NYSE:MOH) upgraded to Buy with a $169 (27% upside) price target at Jefferies.
- Magellan Health (NASDAQ:MGLN) downgraded to Market Perform at Leerink.
- Perrigo (NASDAQ:PRGO) downgraded to Hold with a $72 (10% upside) price target at Berenberg. Shares down a fraction premarket.
- Sabra HealthCare REIT (NASDAQ:SBRA) downgraded to Neutral with a $21 (flat) price target at Mizuho Securities. Shares up a fraction premarket.
- Now read: Daily Insider Ratings Round Up 11/9/18
Original article